Study finds that weight loss after obesity surgery can rapidly restore testosterone production and sex drive in morbidly obese men

May 25, 2018

New research presented at this year's European Congress on Obesity (ECO) in Vienna, Austria (23-26) May shows that weight reduction following a sleeve gastrectomy (obesity surgery), which reduces the size of the stomach, can rapidly reverse obesity-related hypogonadism in morbidly obese men, restoring normal levels of testosterone and sex drive. The study was conducted by Prof Marco Rossato and colleagues at the University of Padova, Italy.

Obesity in men is associated with hypogonadism; a condition in which production of testosterone is reduced, while estrogen levels are elevated. These effects seem to be the result of excess body fat interfering with sex steroid metabolism which leads to increased aromatisation of androgens (such as testosterone) into estrogens within the adipose tissue itself. It follows that weight loss should improve this hormonal imbalance, and contribute to a reversal of hypogonadism.

Research conducted so far has been limited to evaluating the effects of weight loss on male hypogonadism a long time after the reduction in body fat has occurred, so it was not known how rapidly hormones began to return to normal in human subjects. The goal of this study was to investigate levels of sex steroids immediately after rapid weight loss in a group of obese men who had undergone bariatric surgery, to determine how quickly those changes occurred.

The authors selected a group of 29 obese men with an average age of 40.5 years and an average body mass index (BMI) of 43.4kg/m2 (morbidly obese is defined as >40kg/m2). Blood tests were performed to measure total plasma testosterone, the sex hormones dihydrotestosterone (DHT), estradiol, luteinising hormone (LH), follicle-stimulating hormone (FSH), as well as sex hormone binding globulin (SHBG), prostatic-specific antigen (PSA), and leptin in subjects before and one month after they underwent a sleeve gastrectomy to reduce the size of the stomach. As a control, the team studied a group of 19 healthy age-matched, non-obese male subjects.

The study found that among the obese subjects, 51.6% had hypogonadism and of those who had subnormal total testosterone, those with metabolic syndrome (45.2%) showed lower plasma testosterone than men without metabolic syndrome. BMI and waist circumference were found to be negatively correlated with total testosterone and plasma LH levels. Obese males had lower plasma testosterone than healthy subjects (10.8 vs. 15.7 nmol/L), higher estradiol levels (124.4 vs. 78.8 pmol/L), lower LH and FSH levels (3.6 and 2.5 vs 5.2 and 5.9 IU/L respectively). No differences were observed between the two groups in their DHT and PSA levels.

One month after the sleeve gastrectomy, obese subjects showed a significant weight reduction, averaging 17.2 kg and the proportion with hypogonadism had fallen to 11.6%. Average testosterone levels increased by 85%, to a level greater than that observed in the healthy control group (18.9 vs 15.7 nmol/L). Estradiol levels fell by 35% while PSA levels rose by 70%.

The study demonstrates that while obese males show an elevated prevalence of hypogonadism, this is rapidly reversed (within one month) after significant weight loss following bariatric surgery. Testosterone levels are increased significantly while estradiol levels fall due to the rapid and significant loss of fat mass and the consequent decrease in aromatization of androgens to estrogens that typically occur in adipose tissue.

The authors note that: "The clinical significance of the rapid increase in PSA plasma levels observed one month after bariatric surgery is still obscure and has to be confirmed on a larger number of subjects and after a longer period of observation after surgery and weight reduction maintenance".

They suggest that "it could be due to the rapid testosterone increase stimulating the prostate and/or to the rapid reduction in plasma volume after weight loss".

The authors also add a note of caution regarding low PSA levels that can be observed in obese men, since these can underestimate the true levels of PSA that would be seen if these men were normal weight. They say: "If you consider that obese males, as with all people with obesity, have higher prevalence of some type of cancer, including prostate cancer for men, this information could be of importance, since it could lead to doctors potentially missing cases of severe prostate disease in obese men."
-end-


European Association for the Study of Obesity

Related Obesity Articles from Brightsurf:

11 years of data add to the evidence for using testosterone therapy to treat obesity, including as an alternative to obesity surgery
New research covering 11 years of data presented at this year's European and International Congress on Obesity (ECOICO 2020) show that, in obese men suffering from hypogonadism (low testosterone), treatment with testosterone injections lowers their weight and improves a wide range of other metabolic parameters.

Overlap between immunology of COVID-19 and obesity could explain the increased risk of death in people living with obesity, and also older patients
Data presented in a special COVID-19 session at the European and International Congress on Obesity (ECOICO 2020) suggests that there are overlaps between the immunological disturbances found in both COVID-19 disease and patients with obesity, which could explain the increased disease severity and mortality risk faced by obese patients, and also elderly patients, who are infected by the SARS-CoV-2 virus that causes COVID-19 disease.

New obesity guideline: Address root causes as foundation of obesity management
besity management should focus on outcomes that patients consider to be important, not weight loss alone, and include a holistic approach that addresses the root causes of obesity, according to a new clinical practice guideline published in CMAJ (Canadian Medical Association Journal) http://www.cmaj.ca/lookup/doi/10.1503/cmaj.191707.

Changing the debate around obesity
The UK's National Health Service (NHS) needs to do more to address the ingrained stigma and discrimination faced by people with obesity, says a leading health psychologist.

Study links longer exposure to obesity and earlier development of obesity to increased risk of type 2 diabetes
Cumulative exposure to obesity could be at least as important as actually being obese in terms of risk of developing type 2 diabetes (T2D), concludes new research published in Diabetologia (the journal of the European Association for the Study of Diabetes [EASD]).

How much do obesity and addictions overlap?
A large analysis of personality studies has found that people with obesity behave somewhat like people with addictions to alcohol or drugs.

Should obesity be recognized as a disease?
With obesity now affecting almost a third (29%) of the population in England, and expected to rise to 35% by 2030, should we now recognize it as a disease?

Is obesity associated with risk of pediatric MS?
A single-center study of 453 children in Germany with multiple sclerosis (MS) investigated the association of obesity with pediatric MS risk and with the response of first-line therapy in children with MS.

Women with obesity prior to conception are more likely to have children with obesity
A systematic review and meta-analysis identified significantly increased odds of child obesity when mothers have obesity before conception, according to a study published June 11, 2019 in the open-access journal PLOS Medicine by Nicola Heslehurst of Newcastle University in the UK, and colleagues.

Obesity medicine association announces major updates to its adult obesity algorithm
The Obesity Medicine Association (OMA) announced the immediate availability of the 2019 OMA Adult Obesity Algorithm, with new information for clinicians including the relationship between Obesity and Cardiovascular Disease, Diabetes Mellitus, Dyslipidemia, and Cancer; information on investigational Anti-Obesity Pharmacotherapy; treatments for Lipodystrophy; and Pharmacokinetics and Obesity.

Read More: Obesity News and Obesity Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.